



## Mepolizumab

Revised: December 3, 2018.

CASRN: 196078-29-2

## Drug Levels and Effects

### Summary of Use during Lactation

No information is available on the clinical use of mepolizumab during breastfeeding. Because mepolizumab is a large protein molecule with a molecular weight of 149,000, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. Until more data become available, mepolizumab should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant.

### Drug Levels

*Maternal Levels.* Relevant published information was not found as of the revision date.

*Infant Levels.* Relevant published information was not found as of the revision date.

### Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

### Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

### Alternate Drugs to Consider

(Asthma) Benralizumab, Omalizumab

## Substance Identification

### Substance Name

Mepolizumab

## CAS Registry Number

196078-29-2

## Drug Class

Breast Feeding

Lactation

Anti-Allergic Agents

Anti-Asthmatic Agents

Antibodies, Monoclonal, Humanized